Urology

Many also don't think testosterone should be considered a schedule III substance

Negative predictive value 75% to 77% for predicting grade group 2 disease at biopsy

IsoPSA can provide more information for biopsy decisions

Change will make it harder to understand cancer diagnoses and trends in transgender people

New prices for enrollees will start in 2027

Health news and commentary gathered by MedPage Today staff

Health news and commentary gathered by MedPage Today staff

Rather than cancer treatments, risk mostly linked to age, comorbidities, and prior CVD events

Also at IKCS, potential marker for immunotherapy use, early promise for novel bispecific antibody

Six-month brain metastasis PFS of 56%, response rate of 71% in fumarate hydratase-deficient RCC

IV fosfomycin was noninferior to piperacillin-tazobactam in pivotal trial

Health news and commentary gathered by MedPage Today staff

At 23 years, prostate cancer mortality was 13% lower among men who underwent screening

No effect on metabolic syndrome but some impact on various components

Oral tebipenem pivoxil's performance was non-inferior to IV imipenem-cilastatin

Fewer deaths in bladder cancer with ctDNA guidance, but not therapy de-escalation in colon cancer

No OS benefit, more toxicity raise questions about widespread use in mHSPC

Major survival benefit in Chinese study elicits applause at ESMO

Study finds longer interval between treatment noninferior to standard of care

EFS, OS improved by 50-60% with perioperative enfortumab vedotin plus pembrolizumab

Forty percent reduced risk of death compared with ADT alone in EMBARK trial

Adding immunotherapy showed benefits in BCG-naive non-muscle-invasive bladder cancer

MA plan design may steer patients to specific centers, researchers suggest

Health news and commentary gathered by MedPage Today staff

Kennedy cited two studies, but neither offered proof of causality

Study from across the pond reflects a common U.S. problem

Health news and commentary gathered by MedPage Today staff

As government crackdowns widen, physicians warn of consequences to health

10-year OS equal to prostate-only RT in unfavorable intermediate-risk, favorable high-risk tumors

Double-digit improvement in local recurrence, PFS, cancer-specific survival, OS

Use of the PAM50 signature helped identify patients who would benefit

Adding a lutetium-177 radioligand to radiotherapy doubled PFS, with no increase in toxicity

Research suggests biparametric MRI can save resources and time

Approval of subcutaneous pembrolizumab covers existing solid-tumor indications